No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

New England Biolabs® Introduces NEBNext® Custom RNA Depletion Design Tool and RNA Depletion Core Reagent Set for Customizable RNA Depletion

Editor: What To Know

  • Probes can then be sourced from their preferred oligo provider and can be used with the NEBNext Custom RNA Depletion Core Reagent Set or as additions to the probe sets in other NEBNext RNA Depletion Kits (rRNA removal for human, mouse, rat and bacteria samples, and globin mRNA removal).
  • This problem led us to develop a fully customizable and user-friendly solution that allows scientists to create custom probe sequences which work synergistically with our RNase H-based RNA depletion technology to quickly degrade undesirable RNAs from a broad range of input amounts.
  • And supplementing the probes in the NEBNext rRNA Depletion Kit (Bacteria) with custom probes for the bacillus Eggerthella lenta led to 90% depletion of the ribosomal RNA.

December 1, 2020

New England Biolabs (NEB®) announced further expansion of its RNA depletion product portfolio with the launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent Set. Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA (rRNA). This approach can be applied to any sample, including those from less commonly used organisms, and from difficult sample types such as formalin-fixed paraffin-embedded (FFPE) tissue samples.

“The removal of abundant RNA is a critical step for many RNA-based applications, including RNA sequencing” said Fiona Stewart, Ph.D., Product Portfolio Manager, Next Generation Sequencing at NEB. “However, removing undesirable RNA sequences from atypical samples, which are not compatible with existing RNA depletion kits on the market, is a challenge faced by many researchers. This problem led us to develop a fully customizable and user-friendly solution that allows scientists to create custom probe sequences which work synergistically with our RNase H-based RNA depletion technology to quickly degrade undesirable RNAs from a broad range of input amounts.”

The free NEBNext Custom RNA Depletion Design Tool allows researchers to input their target RNA sequence to obtain custom probe sequences 40 to 60 bases long. Probes can then be sourced from their preferred oligo provider and can be used with the NEBNext Custom RNA Depletion Core Reagent Set or as additions to the probe sets in other NEBNext RNA Depletion Kits (rRNA removal for human, mouse, rat and bacteria samples, and globin mRNA removal).

These kits utilize the NEBNext RNase H-based depletion workflow, which is compatible with 10 ng – 1 µg of high-and low-quality RNA samples. The workflow can be completed in two hours, with only 10 minutes of hands-on time.

New England Biolabs: “This technology has been superb for eliminating the ribosomal RNA for a range of custom projects, including tracking novel viruses in mosquitoes, longitudinal profiling for astronauts, and host-pathogen interactions in COVID samples,” said Dr. Christopher Mason, a geneticist and recent user. “Any species can now have a rich, in-depth profile created of its complex transcriptome, from non-coding RNAs to RNA modifications.”

“The open-access tool to design sequences for rRNA removal that NEB is providing to the research community has been very useful for us,” said Vladimir Benes, Head of Genomics Core Facility at the European Molecular Biology Laboratory. “This method for customization of RNA depletion has proven valuable for a range of organisms. Use of custom probes for Xenopus laevis ribosomal RNA worked very well, resulting in complete depletion. And supplementing the probes in the NEBNext rRNA Depletion Kit (Bacteria) with custom probes for the bacillus Eggerthella lenta led to 90% depletion of the ribosomal RNA.” More here.

Other Biotechnology News

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Preci and Biopredic International Partner for Higher Performance of Suspended Pooled Hepatocytes with Extended Longevity and Large-scale Availability

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.

The Future of Biotechnology: Insights Into Cutting-Edge Developments

The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.

Advancing Patient Care: LyGenesis Doses First Patient in Phase 2a Trial

"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."

spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy